CN106559985A - 用免疫球蛋白单可变结构域治疗ttp的方法及其用途 - Google Patents

用免疫球蛋白单可变结构域治疗ttp的方法及其用途 Download PDF

Info

Publication number
CN106559985A
CN106559985A CN201580040020.4A CN201580040020A CN106559985A CN 106559985 A CN106559985 A CN 106559985A CN 201580040020 A CN201580040020 A CN 201580040020A CN 106559985 A CN106559985 A CN 106559985A
Authority
CN
China
Prior art keywords
polypeptide
vwf
amino acid
ttp
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580040020.4A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯蒂安·杜比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Publication of CN106559985A publication Critical patent/CN106559985A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580040020.4A 2014-06-16 2015-06-16 用免疫球蛋白单可变结构域治疗ttp的方法及其用途 Pending CN106559985A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2013007 2014-06-16
NL2013007A NL2013007B1 (en) 2014-06-16 2014-06-16 Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
US201462030817P 2014-07-30 2014-07-30
US62/030,817 2014-07-30
PCT/EP2015/063493 WO2015193326A1 (en) 2014-06-16 2015-06-16 Methods of treating ttp with immunoglobulin single variable domains and uses thereof

Publications (1)

Publication Number Publication Date
CN106559985A true CN106559985A (zh) 2017-04-05

Family

ID=51541255

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580040020.4A Pending CN106559985A (zh) 2014-06-16 2015-06-16 用免疫球蛋白单可变结构域治疗ttp的方法及其用途

Country Status (15)

Country Link
US (5) US10858445B2 (enExample)
EP (6) EP3366305B1 (enExample)
JP (3) JP6688746B2 (enExample)
KR (2) KR102403388B1 (enExample)
CN (1) CN106559985A (enExample)
AU (2) AU2015276237B2 (enExample)
CA (1) CA2952103A1 (enExample)
ES (5) ES2843642T3 (enExample)
IL (1) IL249540B (enExample)
NL (1) NL2013007B1 (enExample)
PL (5) PL3366305T3 (enExample)
PT (5) PT3154569T (enExample)
RU (1) RU2704444C2 (enExample)
SG (2) SG10201811109PA (enExample)
WO (1) WO2015193326A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107340225A (zh) * 2017-07-13 2017-11-10 徐州医科大学 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
CN111670202A (zh) * 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法
US12269893B2 (en) 2014-06-16 2025-04-08 Ablynx N.V. Methods of treating TTP with immunoglobulin single variable domains and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302984A (en) * 2020-11-18 2023-07-01 Green Cross Corp Adamts13 variant having increased escaping rate or activity against autoantibody
WO2023044272A1 (en) 2021-09-17 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
US20240409666A1 (en) * 2021-12-10 2024-12-12 Renhao Li Polypeptides That Bind to von Willebrand Factor (VWF) A1 Domain or an Autoinhibitory Module, Variants, and Uses Thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122825A2 (en) * 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor
CN103189074A (zh) * 2010-11-05 2013-07-03 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
WO2000046383A2 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
WO2001009300A2 (en) 1999-08-02 2001-02-08 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
RU2524129C2 (ru) 2003-01-10 2014-07-27 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
AU2003264053A1 (en) 2003-08-12 2005-03-10 William M. Yarbrough Treatment for acne vulgaris and method of use
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
JP4829897B2 (ja) 2005-01-14 2011-12-07 アブリンクス ナームローゼ フェンノートシャップ 血小板減少及び／又はフォンビルブラント因子（ｖＷＦ）と血小板との間の自発的相互作用によって特徴づけられる疾患及び障害の異なる形態を区別する方法及びアッセイ
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
AU2008219216A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
NZ581097A (en) 2007-05-24 2012-03-30 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
CA2718081A1 (en) 2008-03-21 2009-09-24 Ablynx Nv Von willebrand factor specific binders and methods of use therefor
WO2010056550A1 (en) 2008-10-29 2010-05-20 Wyeth Llc Methods for purification of single domain antigen binding molecules
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
EP2506874A1 (en) 2009-12-01 2012-10-10 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
DK3412305T3 (da) 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
MX2020008294A (es) 2018-02-06 2020-11-18 Ablynx Nv Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122825A2 (en) * 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor
CN103189074A (zh) * 2010-11-05 2013-07-03 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FILIP CALLEWAERT ET AL: "Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura", 《BLOOD》 *
FLORA PEYVANDI ET AL: "Nanobodies-Inspired by nature First results of the Phase II TITAN trial: anti-von Willebrand factor Nanobody as adjunctive treatment for patients with acquired thrombotic thrombocytopenic purpura", 《互联网文献》 *
JOSEFIN-BEATE HOLZ: "The TITAN trial – Assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura", 《TRANSFUSION AND APHERESIS SCIENCE》 *
KENT CHAPMAN ET AL: "Therapy for Thrombotic Thrombocytopenia Purpura: Past, Present, and Future", 《SEMINARS IN THROMBOSIS AND HEMOSTASIS》 *
厉有名: "《内科疑难病与临床分析》", 31 August 2007, 杭州：浙江大学出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12269893B2 (en) 2014-06-16 2025-04-08 Ablynx N.V. Methods of treating TTP with immunoglobulin single variable domains and uses thereof
CN107340225A (zh) * 2017-07-13 2017-11-10 徐州医科大学 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
CN107340225B (zh) * 2017-07-13 2019-07-05 徐州医科大学 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
CN111670202A (zh) * 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法

Also Published As

Publication number Publication date
JP6688746B2 (ja) 2020-04-28
US10858445B2 (en) 2020-12-08
HK1256730A1 (en) 2019-10-04
EP3335724A1 (en) 2018-06-20
HK1256731A1 (en) 2019-10-04
SG11201610488QA (en) 2017-01-27
PT3366305T (pt) 2020-12-21
AU2021202747A1 (en) 2021-05-27
HK1258508A1 (en) 2019-11-15
PL3335724T3 (pl) 2022-09-19
IL249540A0 (en) 2017-02-28
KR20170015513A (ko) 2017-02-08
PT3335724T (pt) 2022-08-02
US20180155442A1 (en) 2018-06-07
RU2017100077A3 (enExample) 2018-12-25
EP4059513A1 (en) 2022-09-21
WO2015193326A1 (en) 2015-12-23
ES2881331T3 (es) 2021-11-29
NL2013007B1 (en) 2016-07-05
EP3332800B1 (en) 2020-08-26
EP3335723A1 (en) 2018-06-20
JP2017519762A (ja) 2017-07-20
PL3366305T3 (pl) 2021-06-14
ES2831865T3 (es) 2021-06-09
PT3332800T (pt) 2020-11-19
KR20220053040A (ko) 2022-04-28
KR102568585B1 (ko) 2023-08-18
JP2020097600A (ja) 2020-06-25
PL3154569T3 (pl) 2021-11-02
EP3154569B1 (en) 2021-04-21
RU2019131713A (ru) 2019-11-11
US20180155441A1 (en) 2018-06-07
EP3154569A1 (en) 2017-04-19
JP2022160431A (ja) 2022-10-19
EP3332800A1 (en) 2018-06-13
US10919980B2 (en) 2021-02-16
EP3335724B1 (en) 2022-06-22
RU2704444C2 (ru) 2019-10-28
EP3366305B1 (en) 2020-11-18
US20180155440A1 (en) 2018-06-07
PL3332800T3 (pl) 2021-04-19
EP3335723B1 (en) 2022-03-30
EP3366305A1 (en) 2018-08-29
CA2952103A1 (en) 2015-12-23
ES2915473T3 (es) 2022-06-22
US20170210822A1 (en) 2017-07-27
AU2015276237B2 (en) 2021-02-25
RU2017100077A (ru) 2018-07-12
KR102403388B1 (ko) 2022-06-03
JP7105260B2 (ja) 2022-07-22
IL249540B (en) 2021-09-30
PT3154569T (pt) 2021-06-22
AU2021202747B2 (en) 2024-02-15
ES2924199T3 (es) 2022-10-05
US20180155443A1 (en) 2018-06-07
SG10201811109PA (en) 2019-01-30
PL3335723T3 (pl) 2022-07-18
US12269893B2 (en) 2025-04-08
PT3335723T (pt) 2022-05-20
AU2015276237A1 (en) 2017-01-19
ES2843642T3 (es) 2021-07-19

Similar Documents

Publication Publication Date Title
JP7105260B2 (ja) 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用
JP2024001135A (ja) Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法
HK40078326A (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof
RU2807602C2 (ru) Способы лечения ттп иммуноглобулиновыми одиночными вариабельными доменами и их применение
HK1255930A1 (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1255930B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1258508B (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof
HK1256731B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1256730B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1236434B (en) Immunoglobulin single variable domains for use in treating ttp

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination